Cytek Biosciences Inc (STU:8EQ)
€ 6.1 0 (0%) Market Cap: 798.13 Mil Enterprise Value: 547.18 Mil PE Ratio: 0 PB Ratio: 2.16 GF Score: 60/100

Q3 2022 Cytek Biosciences Inc Earnings Call Transcript

Nov 09, 2022 / 09:30PM GMT
Release Date Price: €14.1 (-2.76%)
Operator

Welcome to Cytek's Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. (Operator Instructions) I would now like to hand the call over to Paul Goodson, Investor Relations. Please go ahead.

Paul D. Goodson
Cytek Biosciences, Inc. - Head of IR

Thank you, operator. Earlier today, Cytek Biosciences released financial results for the quarter ended September 30, 2022. If you have not received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to [email protected]. Joining me today from Cytek are Wenbin Jiang, CEO; and Patrik Jeanmonod, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during the call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities and financial projections. These statements are based on the company's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot